|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CSPP1 |
Gene summary for CSPP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CSPP1 | Gene ID | 79848 |
| Gene name | centrosome and spindle pole associated protein 1 | |
| Gene Alias | CSPP | |
| Cytomap | 8q13.1-q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000910 | UniProtAcc | Q1MSJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79848 | CSPP1 | CCI_2 | Human | Cervix | CC | 5.75e-20 | 1.46e+00 | 0.5249 |
| 79848 | CSPP1 | CCI_3 | Human | Cervix | CC | 7.53e-04 | 6.51e-01 | 0.516 |
| 79848 | CSPP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.39e-14 | -4.97e-01 | 0.0155 |
| 79848 | CSPP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.47e-04 | -4.30e-01 | -0.1808 |
| 79848 | CSPP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.14e-02 | -3.26e-01 | -0.0811 |
| 79848 | CSPP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.30e-02 | -4.55e-01 | -0.1526 |
| 79848 | CSPP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.64e-09 | -3.91e-01 | -0.1464 |
| 79848 | CSPP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.65e-05 | -3.26e-01 | -0.1001 |
| 79848 | CSPP1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.85e-02 | -4.46e-01 | -0.0842 |
| 79848 | CSPP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.73e-07 | -3.90e-01 | 0.096 |
| 79848 | CSPP1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.20e-11 | -4.39e-01 | 0.0674 |
| 79848 | CSPP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.32e-08 | -4.09e-01 | 0.294 |
| 79848 | CSPP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.05e-06 | -4.09e-01 | 0.3005 |
| 79848 | CSPP1 | A001-C-207 | Human | Colorectum | FAP | 1.32e-02 | -2.62e-01 | 0.1278 |
| 79848 | CSPP1 | A015-C-203 | Human | Colorectum | FAP | 1.74e-14 | -2.66e-01 | -0.1294 |
| 79848 | CSPP1 | A015-C-204 | Human | Colorectum | FAP | 3.33e-03 | -1.60e-01 | -0.0228 |
| 79848 | CSPP1 | A014-C-040 | Human | Colorectum | FAP | 1.44e-03 | -4.07e-01 | -0.1184 |
| 79848 | CSPP1 | A002-C-201 | Human | Colorectum | FAP | 5.22e-08 | -1.99e-01 | 0.0324 |
| 79848 | CSPP1 | A001-C-119 | Human | Colorectum | FAP | 5.57e-03 | -1.41e-01 | -0.1557 |
| 79848 | CSPP1 | A001-C-108 | Human | Colorectum | FAP | 6.09e-08 | -5.18e-02 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
| GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
| GO:00513021 | Cervix | CC | regulation of cell division | 39/2311 | 177/18723 | 2.05e-04 | 2.33e-03 | 39 |
| GO:00009107 | Cervix | CC | cytokinesis | 37/2311 | 173/18723 | 5.40e-04 | 5.23e-03 | 37 |
| GO:0032465 | Cervix | CC | regulation of cytokinesis | 22/2311 | 92/18723 | 1.55e-03 | 1.20e-02 | 22 |
| GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
| GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
| GO:00009101 | Colorectum | SER | cytokinesis | 45/2897 | 173/18723 | 2.28e-04 | 3.93e-03 | 45 |
| GO:00009102 | Colorectum | MSS | cytokinesis | 49/3467 | 173/18723 | 1.02e-03 | 1.02e-02 | 49 |
| GO:00457871 | Colorectum | MSS | positive regulation of cell cycle | 80/3467 | 313/18723 | 1.15e-03 | 1.12e-02 | 80 |
| GO:0090068 | Colorectum | MSS | positive regulation of cell cycle process | 60/3467 | 236/18723 | 5.01e-03 | 3.46e-02 | 60 |
| GO:00457872 | Colorectum | FAP | positive regulation of cell cycle | 66/2622 | 313/18723 | 3.66e-04 | 4.63e-03 | 66 |
| GO:00900681 | Colorectum | FAP | positive regulation of cell cycle process | 48/2622 | 236/18723 | 4.53e-03 | 3.08e-02 | 48 |
| GO:00009103 | Colorectum | FAP | cytokinesis | 37/2622 | 173/18723 | 5.10e-03 | 3.37e-02 | 37 |
| GO:00457873 | Colorectum | CRC | positive regulation of cell cycle | 55/2078 | 313/18723 | 3.76e-04 | 5.57e-03 | 55 |
| GO:00009104 | Colorectum | CRC | cytokinesis | 34/2078 | 173/18723 | 6.47e-04 | 8.55e-03 | 34 |
| GO:00900682 | Colorectum | CRC | positive regulation of cell cycle process | 39/2078 | 236/18723 | 7.23e-03 | 4.98e-02 | 39 |
| GO:00009108 | Endometrium | AEH | cytokinesis | 40/2100 | 173/18723 | 6.01e-06 | 1.49e-04 | 40 |
| GO:00457877 | Endometrium | AEH | positive regulation of cell cycle | 56/2100 | 313/18723 | 2.73e-04 | 3.14e-03 | 56 |
| GO:00900686 | Endometrium | AEH | positive regulation of cell cycle process | 41/2100 | 236/18723 | 2.94e-03 | 2.09e-02 | 41 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CSPP1 | SNV | Missense_Mutation | rs753413923 | c.2951N>A | p.Arg984Lys | p.R984K | Q1MSJ5 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| CSPP1 | SNV | Missense_Mutation | rs369228037 | c.2299N>T | p.Arg767Trp | p.R767W | Q1MSJ5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CSPP1 | SNV | Missense_Mutation | c.3101N>C | p.Leu1034Ser | p.L1034S | Q1MSJ5 | protein_coding | tolerated(0.32) | probably_damaging(0.936) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| CSPP1 | SNV | Missense_Mutation | c.2584N>G | p.Gln862Glu | p.Q862E | Q1MSJ5 | protein_coding | tolerated(0.58) | benign(0.011) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CSPP1 | SNV | Missense_Mutation | c.3360N>T | p.Lys1120Asn | p.K1120N | Q1MSJ5 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CSPP1 | SNV | Missense_Mutation | c.38N>T | p.Ser13Leu | p.S13L | Q1MSJ5 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CSPP1 | SNV | Missense_Mutation | c.124N>C | p.Asp42His | p.D42H | Q1MSJ5 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CSPP1 | SNV | Missense_Mutation | c.520N>A | p.Gln174Lys | p.Q174K | Q1MSJ5 | protein_coding | tolerated(0.21) | benign(0.031) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CSPP1 | SNV | Missense_Mutation | c.1250N>C | p.Gly417Ala | p.G417A | Q1MSJ5 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CSPP1 | SNV | Missense_Mutation | c.3004G>C | p.Asp1002His | p.D1002H | Q1MSJ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |